Financial Performance - For the three months ended March 31, 2023, the group achieved a total revenue of RMB 86,420,934, a decrease of 3.11% compared to RMB 89,195,530 for the same period last year[3] - The gross profit for the same period was RMB 3,052,579, representing a significant decline of 44.40% from RMB 5,489,781 in the previous year[3] - The loss attributable to equity holders of the company was RMB 5,876,609, slightly improved from a loss of RMB 6,043,544 in the same period last year, resulting in a basic loss per share of RMB 0.310 compared to RMB 0.319[3] - The revenue from fertilizer products was RMB 86,245,207, down from RMB 89,086,907 in the previous year, while revenue from elderly care and health services increased to RMB 175,727 from RMB 108,623[6] - The group reported a pre-tax loss of RMB 7,706,292, compared to a loss of RMB 6,111,450 in the previous year[4] - The income tax expense for the period was RMB 724, compared to zero in the same period last year[8] - The company's gross profit for the same period was RMB 3,052,579, representing a significant decline of 44.40% from RMB 5,489,781 year-on-year, with a gross profit margin of 3.53%, down 2.62% from 6.15% in the previous year[14] Expenses and Costs - The group incurred research and administrative expenses of RMB 6,864,118, compared to RMB 6,621,896 in the previous year[4] - The financing costs for the period were RMB 781,536, an increase from RMB 742,591 in the same period last year[4] Dividends and Shareholder Information - The board of directors did not recommend the payment of dividends for the three months ended March 31, 2023[11] - The weighted average number of ordinary shares for calculating basic loss per share remained constant at 1,894,500,000 shares[10] - As of March 31, 2023, major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., holding 182,500,000 shares (9.63% of issued share capital) and Shenzhen Xiangyong Investment Co., holding 180,000,000 shares (9.50%)[24] - The beneficial ownership structure includes significant stakes held by Xiangyong Investment and Guangdong Jiamei Ecological Technology Co., each holding 180,000,000 shares (9.50%)[24] Corporate Governance - The audit committee, consisting of three independent non-executive directors, reviewed the group's performance for the first quarter ending March 31, 2023[27] - The company has adhered to all provisions of the Corporate Governance Code during the review period[31] - There were no arrangements made that would allow directors or their family members to profit from purchasing company shares during the review period[23] - The company reported no competitive interests from directors, supervisors, or management shareholders during the period ending March 31, 2023[26] Strategic Focus and Future Plans - The company is focusing on the bio-composite fertilizer business and elderly care services, targeting the growing elderly population in China, which reached 280 million (19.8% of the total population) by the end of 2022[19] - The company plans to enhance its marketing management and adjust product structures in response to market demand, aiming to improve market share in the composite fertilizer sector[18] - The company is exploring the development of elderly health resource allocation services, including the rental of assistive devices and sales of elderly food products, to create new profit growth points[19] Capital Structure and Financial Position - The company has not issued new shares during the reporting period, maintaining its existing capital structure[14] - The company did not approve any new share option plans during the period ending March 31, 2023[28] - The company did not repurchase any shares during the review period, nor did it purchase, sell, or redeem any shares[30] - The company has no contingent liabilities related to bank loans as of March 31, 2023, maintaining a stable financial position[15] - The company’s bank borrowings are denominated in RMB and are generally renewed annually upon maturity, indicating a conservative treasury policy[17] Industry Outlook - The composite fertilizer industry is expected to stabilize in terms of raw material prices due to supply-demand dynamics and policy adjustments, following a period of rapid development and subsequent industry adjustments[18]

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二三年第一季度業績公告 GEM GEM 香港聯合交易所有限公司（「聯交所」） （「 」）的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公告的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公告的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公 ...

Financial Performance - The total revenue for the year ended December 31, 2022, was RMB 449.676 million, a decrease of 5.6% compared to RMB 476.385 million in 2021[13]. - The gross profit for the same period was RMB 16.395 million, resulting in a gross margin of 3.65%, down from 9.57% in 2021[13]. - The net loss attributable to shareholders for 2022 was RMB 28.106 million, an improvement from a loss of RMB 42.255 million in 2021[13]. - Total assets as of December 31, 2022, amounted to RMB 337.196 million, a decrease from RMB 347.595 million in 2021[13]. - Total liabilities increased to RMB 253.483 million in 2022, compared to RMB 237.236 million in 2021[13]. - The comprehensive gross profit was RMB 16,395,267, with a gross profit margin of 3.67%, significantly down from 9.57% in the previous year[38]. - Sales and distribution costs decreased by 39.17% to RMB 10,516,917, attributed to adjustments in the business model and reduced marketing expenses[39]. - Administrative expenses were RMB 26,971,894, a reduction of 14.28% from RMB 31,466,638 in the previous year, mainly due to decreased depreciation and bad debt losses[42]. - Research and development expenses dropped by 67.52% to RMB 1,136,489, primarily due to changes in the operating model of a subsidiary[43]. - Financing costs increased by 17.09% to RMB 6,401,517, driven by an increase in short-term borrowings to RMB 56,700,000 from RMB 47,400,000 in the previous year[44]. - The net loss attributable to owners for the year was RMB 28,106,065, with a loss per share of RMB 1.48, compared to RMB 42,255,043 and RMB 2.23 per share in 2021[45]. Business Operations - The company operates in two main business areas: bio-composite fertilizers and elderly care services, indicating a diversified business model[6]. - The company has been focusing on the development of new products in the bio-composite fertilizer sector to enhance market competitiveness[6]. - The company plans to expand its elderly care services across the country, indicating a strategic growth initiative[6]. - The company acquired Shanghai Weidi Network Technology Co., Ltd., which has developed a Direct to Consumer (DTC) system platform, facilitating future online sales of health products and compound fertilizers[26]. - The company plans to expand its elderly health resource allocation business, including the sale of elderly food and health products, aiming to develop this segment into a profit growth point[30]. - The company will enhance market marketing management and adjust product structures based on market demand to improve market share[29]. - The company has strengthened safety and epidemic prevention measures in its elderly care services, ensuring stable operations during the COVID-19 pandemic[25]. - The company aims to transition some offline sales of health products and compound fertilizers to the DTC online platform as it matures[30]. - The company plans to enhance market management and adjust product structure based on market demand to increase market share in the compound fertilizer industry[67]. - The company will continue to expand its elderly health product offerings, including rental aids and elderly food sales, to create a new profit growth point[68]. Market Trends and Challenges - In the first half of 2022, the prices of raw materials for compound fertilizers continued to rise significantly due to global inflation and the Russia-Ukraine conflict, impacting production costs[22]. - The compound fertilizer industry is entering a transformation phase, with companies adjusting product structures to seek upgrades and higher competitive stages[29]. - The aging population in China reached 280 million, accounting for 19.8% of the total population, highlighting the potential growth in the elderly care service industry[68]. - The company is developing a Direct to Consumer (DTC) system platform to transition some elderly health products and compound fertilizers to online sales[68]. Corporate Governance - The company is committed to ensuring the accuracy and completeness of its financial reporting, as stated by its board of directors[1]. - The board consists of 2 executive directors, 3 non-executive directors, and 3 independent non-executive directors, with a total of 9 members as per the company's articles of association[135]. - The audit committee held five meetings during the fiscal year and reviewed the financial performance for the year ending December 31, 2022[126]. - The company has implemented a comprehensive risk management and internal control system to ensure compliance with applicable laws and regulations[140]. - The company has arranged professional training for all directors and senior management regarding the GEM listing rules to mitigate legal risks[143]. - The independent non-executive directors have confirmed their independence according to GEM listing rules, ensuring compliance with governance standards[142]. - The company is committed to maintaining transparency and effective communication with shareholders, ensuring their opinions are conveyed to the board[136]. Environmental and Social Responsibility - The company is committed to sustainable development and has adopted policies to promote social and environmental sustainability[27]. - The group focuses on environmental protection and has implemented clean production practices[180]. - The group ensures that all solid waste is comprehensively utilized and treated according to regulations[183]. - The group adheres to national environmental standards for air, water, and noise pollution[184]. - The company has established a corporate social responsibility strategy centered on caring for employees, the environment, and society[179]. - The company has implemented a clean production audit since 2012, promoting energy saving and pollution reduction among employees[187]. Shareholder Information - The company issued a total of 199,500,000 new shares at a subscription price of HKD 0.25 per share, raising a net amount of HKD 49,225,000 for operational funding in elderly care services[50]. - Major shareholders include State-owned Assets Management with 182,500,000 shares (9.63%), Xiangyong Investment with 180,000,000 shares (9.50%), and Guangdong Jiamei with 180,000,000 shares (9.50%) as of December 31, 2022[119]. - The company did not repurchase any shares during the fiscal year ending December 31, 2022[124]. - No new share option plans were approved during the fiscal year ending December 31, 2022[125]. - Shareholders holding at least 10% of the issued share capital can request a special general meeting[172]. - Shareholders with at least 5% of the issued shares can propose new resolutions for discussion at the annual general meeting[174].

天津泰達生物醫學工程股份有限公司 Tianjin TEDA Biomedical Engineering Company Limited （於中華人民共和國註冊成立的股份有限公司） 8189 （股份代號： ） 二零二二年度全年業績公佈 GEM 香港聯合交易所有限公司（「聯交所」） 的特色 GEM 的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供一個 上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周詳的考慮 後方作出投資決定。 GEM GEM 由於 上市公司普遍為中小型公司，在 買賣的證券可能會較於主板買賣之證券承受 GEM 較大的市場波動風險，同時無法保證在 買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本公佈的內容概不負責，對其準確性或完整性亦不發 表任何聲明，並明確表示概不就因本公佈全部或任何部分內容而產生或因倚賴該等內容而引 致之任何損失承擔任何責任。 GEM GEM 本公佈的資料乃遵照聯交所 證券上市規則（「 上市規則」）而刊載，旨在提供有關天津 泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願就本公佈的資料共同及個 別 ...

次 天 津 泰 速 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關 天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董 ...

次 天 津 泰 速 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有 關天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公 ...

天 津 泰 速 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其它在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所GEM證券上市規則（「GEM上市規則」）而刊載，旨在提供有關 天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公司董事願 ...

Financial Performance - Total assets for the year 2021 amounted to RMB 347,595,000, a decrease from RMB 392,919,000 in 2020[18] - Total liabilities for 2021 were RMB 237,236,000, showing a slight decrease from RMB 237,775,000 in 2020[18] - Shareholders' equity decreased to RMB 100,781,000 in 2021 from RMB 143,036,000 in 2020, reflecting a decline of approximately 29.5%[18] - Revenue for the year ended December 31, 2021, was RMB 476,385 thousand, an increase from RMB 369,355 thousand in 2020, representing a growth of approximately 29%[19] - Gross profit for 2021 was RMB 45,605 thousand, with a gross margin of 9.57%, compared to RMB 40,392 thousand and a gross margin of 10.94% in 2020[19] - The company reported a loss attributable to shareholders of RMB 42,255 thousand in 2021, an improvement from a loss of RMB 47,998 thousand in 2020[19] - The comprehensive gross profit for the same period was RMB 45,604,747, with a gross margin of 9.75%, down from 10.94% in 2020, primarily due to significant increases in raw material procurement prices[41] - The loss attributable to shareholders for the year ended December 31, 2021, was RMB 42,255,043, a decrease from RMB 47,998,435 in 2020, resulting in a loss per share of RMB 2.23 compared to RMB 2.53 in the previous year[50] Business Operations - The company operates in two main business areas: bio-composite fertilizers and elderly care services, with a focus on integrated elderly care management[6] - The company has multiple subsidiaries involved in bio-composite fertilizer research, elderly care services, and health consultation[9] - The company aims to expand its elderly care services across the country, integrating management and operational services[6] - The company is committed to developing new products in the bio-composite fertilizer sector to enhance crop growth[6] - Future strategies include potential construction of proprietary elderly care facilities or communities when appropriate[6] - The company is actively expanding its elderly care services, focusing on a light asset operation model and management consulting for other elderly care institutions[26] - The company has established a flagship store for assistive device rentals, enhancing accessibility for elderly customers[26] - The company is positioned to benefit from the increasing demand for elderly care services due to China's aging population, which reached 264 million people aged 60 and above[31] Market and Sales Strategy - The company experienced significant sales volume growth due to enhanced market sales management, despite rising production costs from raw material price increases[25] - The company plans to strengthen market sales management and adjust product structure to improve efficiency and market share in the compound fertilizer sector[29] - The company anticipates future growth in the compound fertilizer business despite rising raw material costs affecting profit margins[41] - The company plans to enhance marketing management and adjust product structure based on market demand, aiming to improve market share in the compound fertilizer sector[76] - The company aims to become one of the largest and most professional assistive device rental service providers in the Shanghai area[77] Financial Management - Administrative expenses for the year ended December 31, 2021, amounted to RMB 31,466,638, an increase of 33.00% compared to RMB 23,659,940 in 2020[46] - Research and development expenses decreased by 36.57% to RMB 3,498,792 for the year ended December 31, 2021, down from RMB 5,516,185 in 2020[48] - Financing costs surged by 234.19% to RMB 5,467,070 for the year ended December 31, 2021, compared to RMB 1,635,933 in 2020, primarily due to increased bank borrowings[49] - The total bank and other borrowings amounted to RMB 47,400,000 as of December 31, 2021, an increase from RMB 15,800,000 as of December 31, 2020, with a fixed annual interest rate of 5.84%[66] - The group utilized approximately RMB 40,400,000 of the bank credit granted, which was RMB 63,400,000 as of December 31, 2021, compared to RMB 21,600,000 the previous year[69] Governance and Compliance - The company maintains a board of directors consisting of three executive directors, three non-executive directors, and two independent non-executive directors[102] - The CEO, Ms. Sun Li, has extensive experience in investment banking and has held various senior positions in the industry since 1998[103] - The board of directors includes experienced professionals with backgrounds in finance, medicine, and management, enhancing the company's strategic decision-making capabilities[108] - The company has established effective internal controls and risk management procedures as part of its governance practices[144] - The audit committee held six meetings during the fiscal year and reviewed the financial reporting procedures of the group[135] - The company has adhered to the corporate governance code, except for one specific provision[141] - The company has implemented strict measures to manage insider information, with the chairman being the primary responsible person[157] Environmental and Social Responsibility - The company primarily engages in the production and sale of bio-composite fertilizers and provides elderly care and health services, with no significant environmental pollution issues reported in the elderly care sector[188] - In the bio-composite fertilizer business, the company emphasizes energy conservation and environmental protection, implementing clean production practices[188] - The company reported a total greenhouse gas emission of 5,679.78 tons of CO2, with a per product emission of 63.1 kg/t[196] - The total wastewater generated was 2,200 tons, with COD levels maintained at 0.294 tons, adhering to treatment agreements[196] - Solid waste management includes comprehensive utilization of general solid waste, achieving full recycling of waste generated[196] - The company encourages stakeholder engagement for continuous improvement in environmental, social, and governance (ESG) practices[187]

Financial Performance - For the nine months ended September 30, 2021, the group achieved a consolidated revenue of RMB 357,140,151, representing a year-on-year increase of 41.94% compared to RMB 251,610,019 for the same period in 2020[6] - The consolidated gross profit for the nine months ended September 30, 2021, was RMB 38,625,967, reflecting a year-on-year growth of 66.67% from RMB 23,175,044 in 2020[6] - The profit attributable to equity holders for the nine months ended September 30, 2021, was RMB 1,823,539, a significant increase of 111.46% compared to a loss of RMB 15,911,732 in the same period last year[6] - The earnings per share for the nine months ended September 30, 2021, was RMB 0.096, compared to a loss per share of RMB 0.839 for the same period in 2020[7] - The group reported a net profit of RMB 2,075,184 for the three months ended September 30, 2021, compared to a loss of RMB 16,656,589 in the same period last year[7] - The total operating revenue for the nine months ended September 30, 2021, was RMB 357,140,151, representing a year-on-year increase of 41.94% compared to RMB 251,610,019 in 2020[20] - The comprehensive gross profit for the same period was RMB 38,625,967, with a year-on-year growth of 66.67% from RMB 23,175,044 in 2020[20] - The comprehensive gross profit margin increased to 10.82%, up 1.61% from 9.21% in the previous year[20] Costs and Expenses - The sales and distribution costs amounted to RMB 17,036,248, reflecting an 18.49% increase from RMB 14,377,707 in 2020[20] - The group incurred financing costs of RMB 1,417,792 for the nine months ended September 30, 2021, compared to RMB 979,196 in the same period last year[7] - The financing costs rose by 44.79% to RMB 1,417,792 compared to RMB 979,196 in 2020[20] - The group’s research and administrative expenses decreased to RMB 18,774,490 for the nine months ended September 30, 2021, from RMB 22,011,858 in 2020[7] - Research and administrative expenses decreased by 14.71% to RMB 18,774,490 from RMB 22,011,858 in the previous year[20] Dividends and Shareholder Information - The group did not recommend the payment of any dividend for the nine months ended September 30, 2021[6] - As of September 30, 2021, major shareholders include Tianjin Economic and Technological Development Zone State-owned Assets Management Co., Ltd. with 182.5 million shares (9.63%) and Shenzhen Xiangyong Investment Co., Ltd. with 180 million shares (9.50%)[29] - The company’s director, Ms. Sun Li, holds 300 million shares, representing 15.83% of the issued share capital[26] - The company has not approved any new share option plans during the nine months ended September 30, 2021[37] - There were no share buybacks by the company or its subsidiaries during the nine months ended September 30, 2021[39] Corporate Governance - The company has complied with all provisions of the Corporate Governance Code except for the requirement that the roles of Chairman and CEO should be separate, which is currently not met[41] - The Audit Committee, consisting of three independent non-executive directors, reviewed the financial reporting procedures and the effectiveness of internal controls for the nine months ended September 30, 2021[36] Business Strategy and Market Trends - The company plans to enhance marketing management and adjust product structure to improve market share in response to the recovery of the compound fertilizer market[24] - The company aims to develop urban sludge treatment business leveraging its compound fertilizer production line, addressing environmental issues while creating value for shareholders[24] - The elderly population in China reached 264 million, accounting for 18.7% of the total population, indicating a deepening aging trend[25] - The company is focusing on a light asset operation model in the elderly care business, providing management consulting services to other elderly care institutions and real estate[25] - The company aims to become one of the largest and most professional assistive device rental service providers in the Shanghai area[25] - The brainwave detection business is developing slowly, but the technology has high advancement and market applicability, and the company is working to expand this business[25] - The company continues to strengthen its professional capabilities in elderly care through collaboration with internationally leading elderly care institutions[25] Executive Compensation - The basic salary of Executive Director Mr. Hao Zhihui was adjusted from RMB 502,500 to RMB 357,032 effective from May 1, 2021, until the end of his service period[34] Legal and Arbitration Matters - SJKGC's audited after-tax profit for the year ended December 31, 2017, was approximately $2.92 million, which did not meet the guaranteed profit of $5.39 million[32] - For the years ended December 31, 2018, and December 31, 2019, SJKGC's audited after-tax profits were $305,000 and $411,000, respectively, both of which did not meet the profit guarantees[33] - The company initiated arbitration against SJK in September 2019 and reached a settlement agreement in December 2020, which was revised in March 2021[33]

头 天 津 泰 建 生 物 醫 學 工 程 股 份 有 限 公 司 Tianjin TEDA Biomedical Engineering Company Limited (於中華人民共和國註冊成立的股份有限公司) (股份代號：8189) 1 天津泰達生物醫學工程股份有限公司 香港聯合交易所有限公司（「聯交所」）GEM（「GEM」）的特色 GEM的定位，乃為相比起其他在聯交所上市的公司帶有較高投資風險的中小型公司提供 一個上市的市場。有意投資的人士應了解投資於該等公司的潛在風險，並應經過審慎周 詳的考慮後方作出投資決定。 由於GEM上市公司普遍為中小型公司，在GEM買賣的證券可能會較於主板買賣之證券承 受較大的市場波動風險，同時無法保證在GEM買賣的證券會有高流通量的市場。 香港交易及結算所有限公司及聯交所對本報告的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本報告全部或任何部分內容而產生或因倚賴該等 內容而引致之任何損失承擔任何責任。 本報告的資料乃遵照聯交所《GEM證券上市規則》（「GEM上市規則」）而刊載，旨在提供有 關天津泰達生物醫學工程股份有限公司（「本公司」）的資料；本公 ...